SE0002148817
© PR Newswire
19.12.2025
HNSA
LISTED
STO
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
News Preview
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response FDA has granted Hansa Biopharma Fast Track and...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2025
HNSA
LISTED
STO
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
News Preview
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response FDA has granted Hansa Biopharma Fast Track and...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
30.10.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
29.10.2025
HNSA
LISTED
STO
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
News Preview
LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical Colleg...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
HNSA
LISTED
STO
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
News Preview
LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical Colleg...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
HNSA
LISTED
STO
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
News Preview
At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001)Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
HNSA
LISTED
STO
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
News Preview
At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001)Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
HNSA
LISTED
STO
Hansa Biopharma announces key executive appointments to support continued growth
News Preview
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
HNSA
LISTED
STO
Hansa Biopharma announces key executive appointments to support continued growth
News Preview
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
News Preview
Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
Renée Aguiar-Luca...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
News Preview
Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
Renée Aguiar-Luca...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
08.07.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
News Preview
LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Dr Philipson has over 25 years of industry...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
News Preview
LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Dr Philipson has over 25 years of industry...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
HNSA
LISTED
STO
Hansa Biopharma to attend BIO International Convention
News Preview
LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19.
Aguiar-Lucander will participate in a panel entitled "European Biotech: U...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
HNSA
LISTED
STO
Hansa Biopharma to attend BIO International Convention
News Preview
LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19.
Aguiar-Lucander will participate in a panel entitled "European Biotech: U...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
HNSA
LISTED
STO
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
News Preview
LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025 at 14:00 CEST / 8:00 AM EDT. Pre-registration is required and can be found at this link.
Presentations by Dr. David R. Cornblath, MD,...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
HNSA
LISTED
STO
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
News Preview
LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025 at 14:00 CEST / 8:00 AM EDT. Pre-registration is required and can be found at this link.
Presentations by Dr. David R. Cornblath, MD,...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
HNSA
LISTED
STO
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
News Preview
LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotlan...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
HNSA
LISTED
STO
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
News Preview
LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotlan...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
News Preview
LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Maria Törnsén has more than 20 yea...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
News Preview
LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Maria Törnsén has more than 20 yea...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
HNSA
LISTED
STO
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
News Preview
Strong product sales and key progress in pipeline catalysts
LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.
Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered strong growth with tot...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
HNSA
LISTED
STO
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
News Preview
Strong product sales and key progress in pipeline catalysts
LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.
Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered strong growth with tot...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
HNSA
LISTED
STO
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.
Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "Hansa delivered several important milestones in 2024 and remains on track to advance innovative science and...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
HNSA
LISTED
STO
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.
Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "Hansa delivered several important milestones in 2024 and remains on track to advance innovative science and...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
HNSA
LISTED
STO
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
News Preview
LUND, Sweden, March 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 confirmatory study in Europe investigating the one-year patient and graft survival in highly sensitized...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
HNSA
LISTED
STO
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
News Preview
LUND, Sweden, March 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 confirmatory study in Europe investigating the one-year patient and graft survival in highly sensitized...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.
The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.
The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
HNSA
LISTED
STO
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
News Preview
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the Int...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
HNSA
LISTED
STO
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
News Preview
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the Int...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
News Preview
Data from the trial is expected to be shared in 2025
LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
News Preview
Data from the trial is expected to be shared in 2025
LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
HNSA
LISTED
STO
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
News Preview
LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
HNSA
LISTED
STO
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
News Preview
LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
HNSA
LISTED
STO
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing pot...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
HNSA
LISTED
STO
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing pot...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
HNSA
LISTED
STO
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
News Preview
LUND, Sweden, Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C. Wainwright on Wednesday, September 11 at 8:00 AM EST. Mr. Tsao's research focuses on biopharmaceuticals and specialty pharmaceuticals. Th...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
HNSA
LISTED
STO
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
News Preview
LUND, Sweden, Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C. Wainwright on Wednesday, September 11 at 8:00 AM EST. Mr. Tsao's research focuses on biopharmaceuticals and specialty pharmaceuticals. Th...
Themefolio
Profiler
Peergroup
© PR Newswire
23.08.2024
HNSA
LISTED
STO
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
News Preview
LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and...
Themefolio
Profiler
Peergroup
© PR Newswire
23.08.2024
HNSA
LISTED
STO
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
News Preview
LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
